Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2019 3
2020 3
2021 4
2023 1
2024 3
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigators. Lu S, et al. N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828946 Clinical Trial.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Spicer JD, et al. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Free PMC article. Clinical Trial.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Swain SM, et al. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. Lancet Oncol. 2020. PMID: 32171426 Clinical Trial.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer: Secondary Analysis of a Randomized Clinical Trial.
Bastos DA, Soares A, Schutz FAB, Cronemberger E, de Almeida Luz M, Martins SPDS, Muniz DQB, Cárcano FM, Smaletz O, Peixoto FA, Gomes AJ, Cruz FM, Franke FA, Herchenhorn D, Gidekel R, Werutsky G, Rebelatto TF, Gomes de Jesus R, Souza VC, Fay AP, Maluf FC. Bastos DA, et al. JAMA Netw Open. 2025 Jan 2;8(1):e2454253. doi: 10.1001/jamanetworkopen.2024.54253. JAMA Netw Open. 2025. PMID: 39804646 Free PMC article. Clinical Trial.
Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country.
Souza ABA, Barrios C, de Jesus RG, Reinert T, Giacomazzi J, Rosa DD, Cronemberger E, Werutsky G, Bines J, Queiroz GS, Cordeiro de Lima V, Freitas-Junior R, Couto Filho JD, Emerenciano K, Resende H, Crocamo S, Van Eyll B, Neron Y, Dybal V, Lazaretti NS, Costamilan RC, Andrade DAP, Mathias C, Vacaro GZ, Borges G, Morelle AM, Sampaio Filho CA, Mano M, Lichtenfels M, Simon SD, Fay AP. Souza ABA, et al. JCO Glob Oncol. 2025 Mar;11:e2400337. doi: 10.1200/GO-24-00337. Epub 2025 Mar 7. JCO Glob Oncol. 2025. PMID: 40053901
Real-World Data on First-Line Treatment of Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer in Brazil (BRAVE Study).
Werutsky G, Rosa DD, Reinert T, Barroso-Sousa R, Resende H, Signorini P, Cronemberger E, Fagundes JGM, Leal JHS, Guimarães MB, Vieira A, Weis LN, de Figueiredo JMB, Correa TS, Venero FC, Pauletto MM, Franche LMT, Bernardes MM, de Oliveira AHO, de Jesus RG, Gössling G, Bines J. Werutsky G, et al. Clin Breast Cancer. 2025 Dec;25(8):e1040-e1049. doi: 10.1016/j.clbc.2025.05.020. Epub 2025 May 27. Clin Breast Cancer. 2025. PMID: 40581548 Free article.
19 results